Ask those 1,700 local students what they want

Posted

In 2018, RiseVT charted the height and weight of almost all of the elementary school children in Franklin and Grand Isle counties. It involved over 1,700 first, third, and fifth-graders. The study’s purpose was to calculate the percentage of students that was overweight or obese. The expectation, led by years of self-reporting, was around the 20 percent figure. The truth? Double that. A full 41 percent were overweight or obese.

That was seven years ago. The fifth graders are now seniors in high school. The first graders will be freshmen next school year. There has been no follow-up to the study, but it’s a safe bet the number has gone up, after all, over two-thirds of the adult population is overweight or obese.

So what’s happened over those seven years?

The number of people overweight or obese continues to rise. For the first time, the world now has more children who are obese than underweight. It’s expected that the United States will have 260 million people diagnosed as obese by 2050. Over the next decade, the rise in obesity will cost an estimated nine trillion dollars.

That’s an enormous financial burden at our doorstep.

The good news is that the medical community, writ large, is moving toward declaring obesity a disease, not just an issue of people’s diet and lack of exercise. Obesity is now being linked to over 200 medical conditions. Over 85 percent of people with type 2 diabetes are overweight or obese.

Declaring obesity as a disease is an important development for a number of reasons. It subtracts from the stigma; obesity is not a “personal choice,” it’s a disease. It opens the doors for insurance coverage. It opens clinical pathways, which helps with early intervention. It creates, at long last, the sense that a responsible health care system is one that places a strong emphasis on prevention. 

The other advancement is the new class of drugs responsible for helping people lose weight. The drug is the glucagon-like peptide [GLP-1] - Ozempic for diabetes and Wegovy for weight loss. Scientists are calling the drug “the most important drug-class breakthrough in medical history.”

The drugs are so effective that it’s no longer appropriate [or accurate] to say managing one’s weight is all about willpower. That’s simply not true. Not only that, the GLP-1 drugs are being investigated as important tools to fight sleep apnea, heart disease, Alzheimer’s, inflammation, liver and gut issues, and the ageing process. Among others. It’s also being researched for its potential role in fighting addiction and various brain disorders.

It’s probably the most exciting thing happening in health care. It may be what helps give those 1,700 Franklin and Grand Isle students a healthier, longer life.

The immediate challenge is to get the drugs to the people who need them the most. They are prohibitively expensive for most people. And there is the hesitancy to take a drug that requires the patient to be on it for a substantial amount of time. 

But those challenges are likely to be short-lived. The cost of the drugs will drop as patents expire and generics take their place. It’s also expected that as the drugs improve, the need to take a “forever drug” will be reduced.

But, we should not content ourselves with the thought that this will happen on its own. If 90 cents of every health care dollar spent goes to treating chronic disease, and obesity is at the center of all chronic diseases, then why wouldn’t the government see fit to subsidize the cost? Isn’t the goal to delay the onset of disease, and in so doing reduce [dramatically] the cost of health care?

Ask those 1,700 local students [and their parents.]

By Emerson Lynn

 

Comments

No comments on this item Please log in to comment by clicking here